Local Brazilian companies will be the beneficiaries of a new technology transfer regulation that is intended to reduce the country's dependence on foreign drug imports and technology. 

The regulation, approved by the Board of Brazil's national regulatory agency, Anvisa, on 13 September 2012, establishes procedures for local companies to enter into drug development and technology transfer partnerships with the National Health Service (SUS).  The regulation expands strategic and practical mechanisms for increasing access to new technologies in Brazil, and will lead to an estimated 25% reduction in the country's dependence on health sector imports.

According to Anvisa, proposed partnerships must have a, "High relevance for public health and for the development of the [Brazilian] health-industrial complex," and must be approved by Brazil's Ministry of Health.  The new regulation has won the support of the Brazilian drug industry association, Farmabrasil.

Read more:

Read all Breaking News from RegLink